|
시장보고서
상품코드
2039131
허셉틴(Herceptin) 바이오시밀러 시장 : 적응증별, 유통 채널별, 지역별Herceptin Biosimilar Market, By Indication (Breast Cancer, Gastric Cancer, Others), By Distribution Channel (Hospitals, Oncology Centers, Others), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
허셉틴 바이오시밀러 시장은 2026년에 52억 7,000만 달러로 추정되며, 2033년까지 100억 7,000만 달러에 이를 전망입니다. 또한 2026-2033년 CAGR은 9.7%를 나타낼 것으로 예측됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 52억 7,000만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR | 9.70% | 예측 금액(2033년) | 100억 7,000만 달러 |
'허셉틴'이라는 브랜드로 판매되는 트라스투주맙은 유방암과 위암 치료에 사용되는 단일클론항체입니다. 허셉틴은 주로 HER2 수용체 양성으로 진단된 암 환자 치료에 사용됩니다. 허셉틴의 작용기전은 유방암 세포 표면에 있는 HER2 수용체에 결합하여 세포가 성장 신호를 받는 것을 억제함으로써 세포의 증식을 억제하는 것입니다. 허셉틴은 유방암 환자를 위한 면역 표적 치료제로 작용합니다.
시장 역학
제품 승인 및 출시는 세계 허셉틴 바이오시밀러 시장의 성장을 견인하는 요인입니다. 예를 들어, 2020년 2월 미국 생명공학 제약기업 화이자는 인간상피세포성장인자수용체(HER2) 양성 유방암 및 전이성 위암 치료를 위한 트라스투주맙 바이오시밀러 '트라지멜라'를 출시했습니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 고찰을 제공합니다.
- 세계 허셉틴 바이오시밀러 시장의 주요 기업 프로파일을 각종 파라미터(기업 개요, 재무 실적, 의약품 포트폴리오, 시장 입지, 유통 전략, 주요 동향 및 전략, 향후 계획 등)에 따라 정리하여 전해드립니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 유형 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 허셉틴 바이오시밀러 시장' 보고서는 투자자, 공급업체, 의료기기 제조업체, 유통업체, 신규 시장 진출기업, 재무 분석가 등 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 허셉틴 바이오시밀러 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 허셉틴 바이오시밀러 시장 : 적응증별(2021년-2033년)
제5장 세계의 허셉틴 바이오시밀러 시장 : 유통 채널별(2021년-2033년)
제6장 세계의 허셉틴 바이오시밀러 시장 : 지역별(2021년-2033년)
제7장 경쟁 구도
제8장 섹션
LSH 26.06.04Herceptin Biosimilar Market is estimated to be valued at USD 5.27 Bn in 2026 and is expected to reach USD 10.07 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 5.27 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.70% | 2033 Value Projection: | USD 10.07 Bn |
Trastuzumab, sold under the brand Herceptin, is a monoclonal antibody used for the treatment of breast cancer and gastric cancer. Herceptin is mainly used to treat patients suffering from cancer and diagnosed with HER2 receptor positive. Herceptin mechanism of action is binding itself to HER2 receptors on the surface of breast cancer cells and blocking them from receiving growth signals and thus decreasing the mutation of cells. Herceptin acts as an immune targeted therapy for breast cancer patients.
Market Dynamics
Product approvals and launches are the factors driving the growth of the global herceptin biosimilar market. For instance, in February 2020, Pfizer Inc., a biotechnology and pharmaceutical company in the U.S., launched the trastuzumab biosimilar, Trazimera, for treatment of human epidermal growth receptor causing breast cancer and metastatic gastric cancer.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global Herceptin biosimilar market based on the following parameters - company overview, financial performance, drugs portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study are Amgen Inc., AryoGen Biopharma, Biocon Limited, Celltrion Inc., Pfizer Inc., Merck & Co., Inc., Accord Healthcare Ltd, Gedeon Richter Plc, Genor Biopharma Company Ltd, Mabion SA, Mylan N.V, Roche Holding AG and Samsungbioepis Co,.Ltd
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future drug launches, drug class up-gradation, market expansion, and marketing tactics
- The global herceptin biosimilar market report caters to various stakeholders in this industry including investors, suppliers, device manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global herceptin biosimilar market.
Market Segmentation
- By Indication
- Breast Cancer
- Gastric Cancer
- Others
- By Distribution Channel
- Hospitals
- Oncology Centers
- Others
- Global Herceptin Biosimilar Market, By Region
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
- Key Players
- Amgen Inc.
- AryoGen Biopharma
- Biocon Limited
- Celltrion Inc.
- Pfizer Inc.
- Merck & Co., Inc.
- Accord Healthcare Ltd
- Gedeon Richter Plc
- Genor Biopharma Company Ltd
- Mabion SA
- Mylan N.V
- Roche Holding AG
- Samsungbioepis Co., Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Indication
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Product Approval
- Collaboration/Merge/Acquisition
- Regulatory Landscape
- PEST Analysis
- Porter's Five Forces Analysis
- Epidemiology
- Robust Pipeline Analysis
4. Global Herceptin Biosimilar Market, By Indication, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Gastric Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
5. Global Herceptin Biosimilar Market, By Distribution Channel, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospital
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Oncology Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Billion)
6. Global Herceptin Biosimilar Market, By Region, 2021 - 2033, (USD Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Billion)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (USD Billion)
- North Africa
- Central Africa
- South Africa
7. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- Company Profile
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- AryoGen Biopharma
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Biocon Limited
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Celltrion Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Accord Healthcare Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Gedeon Richter Plc
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Genor Biopharma Company Ltd
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mabion SA
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Mylan N.V
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Roche Holding AG
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Samsungbioepis Co,.Ltd.
- Company Highlights
- Product Portfolio
- Financial Performance
- Recent Highlights
- Market Strategies
- Analyst Views
8. Section
- References
- Research Methodology
- About Us
